Evidence map›Paper›PMID 42265677›Full record

ArticleBMC medicine2026

The economic burden of depression disease for China, India and the USA in 2025-2050: a health-augmented macroeconomic modelling study.

Meiyu Wu, Andong Li, Kehui Meng, Yangke Yi, Zixuan Zhang, Chaohao Shi, Yongtao He, Xuan Ouyang, Chongqing Tan, Xiaomin Wan

Abstract read
In one paragraph

Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Meiyu WuDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Andong LiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Kehui MengDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Yangke YiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Zixuan ZhangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Chaohao ShiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Yongtao HeDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Xuan OuyangNational Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Chongqing TanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. tanchongqing@csu.edu.cn.
Xiaomin WanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. wanxiaomin@csu.edu.cn.

Funding

Health Research Project of Hunan Provincial Health Commission 20254693Hunan Health Economics And Information Association WJX2025A01Hunan Provincial Natural Science Foundation of China 2026JJ50239Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department NO. CPA-Z05-ZC-2025-003
6 · The paper itself

Abstract

backgroundDepression is an increasingly severe public health challenge worldwide, causing substantial health losses and profoundly impacting national economies. As China, India and the USA bear the largest share of the global depression burden and have different developmental and demographic profiles, quantifying the condition's long-term macroeconomic effects in these countries is crucial for gaining insight into the relationship between mental health and economic development worldwide.

methodsWe used a health-augmented macroeconomic model to assess the macroeconomic impact of depression, comparing the difference in gross domestic product (GDP) between a status quo scenario and a counterfactual scenario in which depression was assumed to be completely eliminated between 2025 and 2050. The model incorporated human and physical capital channels, capturing productivity losses, reduced labour supply and declines in household savings caused by medical expenditures. Data were drawn from multiple publicly available sources, including literature, the Global Burden of Disease Study and the World Bank.

resultsFrom 2025 to 2050, the cumulative macroeconomic burden of depression is projected to reach INT $3,340 billion across the three countries. The USA is expected to bear the largest total and per capita losses, at INT $1,416 billion and INT $4,110 per person respectively. India would follow with INT $1,100 billion and INT $762 per person, while China would account for INT $873 billion and INT $615 per person.

conclusionsAcross different economic models, depression has a significant and sustained negative impact on long-term macroeconomic development. Policymakers should take prompt action to implement effective prevention and management strategies to curb the growing health and economic impacts of depression.

Indexed as

Cost of IllnessDepressionModels, EconomicChinaGross Domestic ProductHealth ExpendituresHumansIndiaUnited StatesChinaDepressionIndiaMacroeconomicModellingUSA

Identifiers

PMID42265677
PMCPMC13474784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.